Juxtapid FAQs

Here are some commonly asked questions about Juxtapid. Just click the question to view the answer. 

How does Juxtapid work?

Juxtapid is a microsomal triglyceride transfer protein (MTP) inhibitor that acts directly in the liver and small intestine to limit the production of the lipids that accumulate aggressively in patients with HoFH.  Learn more here.

How is Juxtapid used?

Juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). Limitations of Use: The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia who do not have HoFH. The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined. 

What are Juxtapid’s Limitations of Use?

Juxtapid's limitations of use include:

  • The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia who do not have HoFH.
  • The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined. 

In addition, the safety and effectiveness have not been established in pediatric patients.

Which patients should not take Juxtapid?

Juxtapid is contraindicated in the following conditions:

  • Pregnancy
  • Concomitant administration of moderate or strong CYP3A4 inhibitors
  • Moderate or severe hepatic impairment or active liver disease including unexplained persistent elevations of serum transaminases

Juxtapid should also not be used by nursing mothers.

What is the Juxtapid REMS Program?

Because of the risk of hepatotoxicity, Juxtapid is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Juxtapid REMS Program. For more information on the Program, visit the Juxtapid REMS Program page.